Immunology and inflammation

News

A female palm containing a Rhapsido tablet

Rhapsido is first drug cleared for chronic hives disorder SD

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.

News

Novartis taps China's Abogen for autoimmunity TCE

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

News

Sanofi forges new $8bn pact with Regeneron

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new drugs.

News

Apogee buy delivers eczema trial win for AbbVie

AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.

News

Iambic files IPO after signing up AbbVie as new partner

In the space of a day, Iambic has filed an IPO, released the latest version of its AI platform, and signed a multi-year alliance with AbbVie.

News

Boehringer signs AI drug discovery deal with Owkin

Boehringer Ingelheim has joined Sanofi and AstraZeneca in signing up to deploy Owkin's AI platform K Pro in its drug discovery operations.

Rhapsido is first drug cleared for chronic hives disorder SD

Novartis taps China's Abogen for autoimmunity TCE

Sanofi forges new $8bn pact with Regeneron

Apogee buy delivers eczema trial win for AbbVie

Iambic files IPO after signing up AbbVie as new partner

Boehringer signs AI drug discovery deal with Owkin

Syndax shares fall as lung fibrosis drug fails trial

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks